These emerging treatments, Tirzepatide , represent a significant advancement in treating obesity and potentially associated ailments . These drugs are categorized as GLP-1 pathway agonists , meaning https://nellcjbc350107.diowebhost.com/96716281/retatrutide-a-deep-dive-into-incretin-compounds